BNP Paribas Aktienanleihe SNW 27..../ DE000PC06L18 /
5/31/2024 9:40:22 PM | Chg.+1.140 | Bid9:58:21 PM | Ask9:58:21 PM | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
100.130EUR | +1.15% | 100.280 Bid Size: 20,000 |
100.380 Ask Size: 20,000 |
SANOFI SA INHABER ... | 90.00 - | 6/27/2024 | Call |
GlobeNewswire
5/31
Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Patients with COPD
GlobeNewswire
5/31
Press Release: Dupixent recommended for EU approval by the CHMP to treat patients with COPD
GlobeNewswire
5/31
Update on FDA Priority Review of Dupixent® (dupilumab) for the Treatment of COPD Patients with Type ...
GlobeNewswire
5/31
Press Release: Update on FDA priority review of Dupixent for the treatment of COPD patients with typ...
GlobeNewswire
5/27
Press Release: Sarclisa accepted for FDA priority review for the treatment of transplant-ineligible ...
GlobeNewswire
5/21
Press Release: Sanofi, Formation Bio and OpenAI announce first-in-class AI collaboration
GlobeNewswire
5/20
Dupixent® (dupilumab) Late-Breaking Data from NOTUS Confirmatory Phase 3 COPD Trial Presented at ATS...
GlobeNewswire
5/20
Press Release: Dupixent® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ...
GlobeNewswire
5/20
Shah Capital Withdraws Proxy Campaign Against Re-Election of Directors at Novavax’s 2024 Annual Meet...
GlobeNewswire
5/13
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 20...
GlobeNewswire
5/13
Fulcrum Therapeutics Enters into a Collaboration and License Agreement with Sanofi for the Developme...
GlobeNewswire
5/13
Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of Adolescents with Chroni...
GlobeNewswire
5/10
Press Release: Sanofi and Novavax announce co-exclusive licensing agreement to co-commercialize COVI...
GlobeNewswire
5/8
IGM Biosciences Announces First Quarter 2024 Financial Results and Provides Corporate Update